

# High Expression of Human 15-Lipoxygenase Induces NF- $\kappa$ B-Mediated Expression of Vascular Cell Adhesion Molecule 1, Intercellular Adhesion Molecule 1, and T-Cell Adhesion on Human Endothelial Cells

HELENA VIITA,<sup>1</sup> CHANDAN K. SEN,<sup>2,3</sup> SASHWATI ROY,<sup>2,3</sup> TARJA SILJAMÄKI,<sup>1</sup>  
TAPIO NIKKARI,<sup>4</sup> and SEPPO YLÄ-HERTTUALA<sup>1,5</sup>

## ABSTRACT

Expression of 15-lipoxygenase (15-LO) is induced over 100-fold in early fatty streak lesions. 15-LO activity leads to the production of specific lipid hydroperoxides, which can have major effects on the expression of proinflammatory genes involved in atherogenesis. We have used retrovirus-mediated gene transfer to achieve stable high expression of 15-LO in human endothelial ECV304 cells. These cells were used to study the effects of 15-LO on the expression of vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1), activation of nuclear factor kappa B (NF- $\kappa$ B), and T-cell adhesion on endothelial cells. NF- $\kappa$ B activation was greatly potentiated by increased 15-LO activity in the stably transduced cells, and both VCAM-1 and ICAM-1 were significantly induced in these cells in response to tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and phorbol 12-myristate 13-acetate (PMA) stimulation, as studied by flow cytometry. The induction of ICAM-1 was sensitive to antioxidants in a dose-dependent manner. The adherence of Jurkat T cells on the 15-LO-expressing endothelial cells was markedly induced after PMA stimulation. These results indicate that 15-LO activity may be involved in the early pathogenesis of atherosclerosis by inducing VCAM-1 and ICAM-1 expression and by increasing T-cell adhesion on the endothelium. *Antiox. Redox Signal.* 1, 83–96.

## INTRODUCTION

**A**THEROSCLEROSIS IS A CHRONIC INFLAMMATORY DISEASE characterized by accumulation of intra- and extracellular lipids, foam cell formation, proliferation of arterial smooth muscle cells, and accumulation of connective tissue components. Among the earliest events in

atherogenesis is the increased adherence and migration of monocytes and T lymphocytes into the subendothelial space (Ross, 1993). Oxidized low-density lipoprotein (LDL) seems to be one of the key pathogenetic factors in this process (Ylä-Herttuala, 1998). Several lines of evidence indicate that 15-lipoxygenase (15-LO) activity may be involved in LDL oxidation and

<sup>1</sup>A.I. Virtanen Institute, University of Kuopio, FIN-70211 Kuopio, Finland.

<sup>2</sup>Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720-3200.

<sup>3</sup>Department of Physiology, Faculty of Medicine, University of Kuopio, FIN-70211 Kuopio, Finland.

<sup>4</sup>Department of Medical Biochemistry, Medical School, University of Tampere, FIN-33101 Tampere, Finland.

<sup>5</sup>Department of Medicine, University of Kuopio, FIN-70211 Kuopio, Finland.

atherogenesis (Sigal, 1991): 15-LO is expressed in atherosclerotic lesions and its expression is greatly induced in early fatty streak lesions (Ylä-Herttuala *et al.*, 1990, 1991; Hiltunen *et al.*, 1995), specific enzyme activity of 15-LO can be detected in atherosclerotic lesions (Kühn *et al.*, 1994; Kühn *et al.*, 1997), 15-LO can induce LDL oxidation (Sparrow *et al.*, 1988; Parthasarathy *et al.*, 1989; McNally *et al.*, 1990; Rankin *et al.*, 1991; Derian and Lewis, 1992), transfer of human 15-LO cDNA into iliac arteries of moderately hypercholesterolemic rabbits resulted in the appearance of oxidized LDL (Ylä-Herttuala *et al.*, 1995), LO inhibitors can reduce atherosclerosis in cholesterol-fed rabbits (Sendobry *et al.*, 1997; Bocan *et al.*, 1998), 12/15-LO knockout mice have reduced capacity to oxidize LDL (Sun and Funk, 1996), and atherosclerosis is accelerated in 15-LO transgenic mice (Harats *et al.*, 1997). However, apart from the possible role of 15-LO in LDL oxidation, other mechanisms for the proatherogenic role of 15-LO have remained unclear (Ylä-Herttuala, 1998; Sigal, 1991). Also, the role of 15-LO as a proatherogenic enzyme has been challenged (Sparrow and Olszewski, 1992; Shen *et al.*, 1996).

While several studies have addressed the role of 15-LO in the oxidative modification of LDL, very little is known about the role of 15-LO in regulating gene expression of proatherogenic molecules, even though lipid hydroperoxides are implied in the amplification of inflammatory signals (Andalibi *et al.*, 1993) and reactive oxygen species activate several transcription factors, including NF- $\kappa$ B (Andalibi *et al.*, 1993; Schreck *et al.*, 1992; Sen and Packer, 1996). In this study, we have used retrovirus-mediated gene transfer (Gilboa *et al.*, 1986) of human reticulocyte 15-LO cDNA into human endothelial cells to achieve stable high expression of 15-LO. These cells were used to study the role of 15-LO in the modulation of the expression of adhesion molecules. Our results show that the transduced cells express 15-LO mRNA and protein and have high 15-LO enzyme activity. The expression of 15-LO markedly potentiated the activation of NF- $\kappa$ B in response to various stimuli, and induced NF- $\kappa$ B-mediated expression of vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1). The induction

was antioxidant sensitive in a dose-dependent manner. Also, the adherence of Jurkat T cells on the 15-LO-expressing cells after phorbol 12-myristate 13-acetate (PMA) stimulation was markedly induced as compared to control cells.

## MATERIALS AND METHODS

### Materials

The cell lines  $\Psi$ 2, PA317, ECV304, and Jurkat T clone E6-1 were obtained from American Type Culture Collection (ATCC, Rockville, MD). Dulbecco's modified Eagle's medium (DMEM), medium 199, RPMI 1640, fetal bovine serum (FBS), newborn calf serum, and penicillin-streptomycin were from Gibco (Life Technologies Ltd., Paisley, Scotland, UK), and polyethylene glycol (PEG) 6000 was from Fluka Chemie AG (Buchs, Switzerland). Polybrene, geneticin, phenylmethylsulfonyl fluoride (PMSF), butylated hydroxytoluene (BHT), SDS molecular weight markers, 4-chloro-1-naphthol, linoleic acid, triheptadecanoin, PMA, and H<sub>2</sub>O<sub>2</sub> were purchased from Sigma Chemical Co. (St. Louis, MO). Oligo(dT)cellulose was from Boehringer Mannheim (Mannheim, Germany), and [ $\alpha$ -<sup>32</sup>P]dCTP and Hybond-N nylon filters were from Amersham International (Amersham, UK). Prime-a-Gene Labeling System, NF- $\kappa$ B probe, and T4 polynucleotide kinase were obtained from Promega Inc. (Madison, WI). X-ray films were purchased from Fuji Photo Film Co., Ltd. (Japan) and nitrocellulose filters were from Schleicher & Schuell (Dassel, Germany). Polyclonal rabbit anti-human recombinant 15-LO antibody (Sigal *et al.*, 1990) was kindly provided by Dr. Elliott Sigal, and affinity-purified horseradish peroxidase-conjugated goat anti-rabbit IgG was obtained from Bio-Rad Laboratories (Richmond, CA). TNF- $\alpha$  was from Genentech Inc. (CA), thapsigargin was from Calbiochem (La Jolla, CA), and poly(dI-dC) and NAP-5 columns were from Pharmacia (Stockholm, Sweden). [ $\gamma$ -<sup>32</sup>P]dATP was from DuPont NEN (Boston, MA), NF- $\kappa$ B mutant oligonucleotide was from Santa Cruz Biotechnology Inc. (CA), and  $\alpha$ -lipoate (racemate mixture) was from ASTA Medica (Frankfurt, Germany). Monoclonal VCAM-1 antibody and fluorescein isothiocyanate (FITC)-coupled

monoclonal ICAM-1 antibody were obtained from Immunotech (Cedex, France), FITC-labeled goat anti-mouse IgG monoclonal antibody was from Coulter (Miami, FL), and calcein acetoxymethyl ester (calcein-AM) was from Molecular Probes (Eugene, OR).

#### *Vector construction*

The retroviral vector pLLORNL (Benz *et al.*, 1995; Ylä-Herttuala *et al.*, 1995) is derived from the pLDRNL vector described by Miyanojara *et al.* (1988). The human LDL receptor cDNA in the pLDRNL vector was replaced with human reticulocyte 15-LO cDNA (Sigal *et al.*, 1988) digested with *Bgl*III at site 2,245. Thus, this construct does not contain the polyadenylation signal present in the original cDNA clone (Sigal *et al.*, 1988). In the pLLORNL vector, the 15-LO cDNA is expressed from the long terminal repeat (LTR) of Moloney murine leukemia virus (van Beveren *et al.*, 1980), Tn5 neomycin phosphotransferase gene (Beck *et al.*, 1982) is expressed from an internal Rous sarcoma virus (RSV) promoter, and a second Moloney murine leukemia virus LTR provides transcriptional termination sequences. The retroviral vector pLZRNL (Sharkey *et al.*, 1990; Ylä-Herttuala *et al.*, 1995) containing the *Escherichia coli lacZ* gene (Kalnins *et al.*, 1983) coding for  $\beta$ -galactosidase was used as a control vector.

#### *Cell lines and culture techniques*

Ecotropic  $\Psi$ 2 (Mann *et al.*, 1983) and amphotropic PA317 (Miller and Buttimore, 1986) mouse fibroblast packaging cell lines were routinely grown in DMEM supplemented with 5% newborn calf serum, 50 U/ml penicillin, and 50  $\mu$ g/ml streptomycin. ECV304 cells were grown in medium 199 supplemented with 10% FBS, 100 U/ml penicillin, and 100  $\mu$ g/ml streptomycin. Growth media were supplemented with 400  $\mu$ g/ml of the neomycin-analog geneticin for selection and culture of neomycin-resistant  $\Psi$ 2 and PA317 clones, and with 600  $\mu$ g/ml geneticin for ECV304 clones.

#### *Transfection and transduction*

Transfections and transductions were made as described (Ausubel *et al.*, 1992). Briefly, the

ecotropic  $\Psi$ 2 packaging cell line was first transfected with the retroviral plasmid pLLORNL by the calcium phosphate precipitation method. The virus stock obtained from the growth medium of the transfected  $\Psi$ 2 cells was filtered and concentrated by PEG precipitation method or by centrifugation. The concentrated virus stock was used to transduce the amphotropic PA317 packaging cell line in the presence of polybrene (8  $\mu$ g/ml). Stably transduced geneticin-resistant PA317 clones were isolated, expanded, and analyzed for 15-LO mRNA production, protein expression, and enzymatic activity. One of the PA317 15-LO clones was chosen for the production of amphotropic virus. This virus stock was concentrated from the growth medium of the PA317 clone by PEG precipitation and was used for the transduction of ECV304 cells. Geneticin-resistant ECV304 clones were isolated, expanded, and analyzed for 15-LO expression. The same procedure was done with the pLZRNL plasmid. The clones were analyzed for  $\beta$ -galactosidase expression, and were used as controls.

#### *Determination of virus titers and detection of helper virus*

Virus titers of the concentrated amphotropic virus stocks were 4–60  $\times 10^4$  cfu/ml as determined using a bioassay on 209F cells. All these stocks were free of helper virus as detected through horizontal spread of drug resistance (Ausubel *et al.*, 1992; Ylä-Herttuala *et al.*, 1995).

#### *mRNA isolation and Northern blotting*

Poly(A)<sup>+</sup> RNA was isolated from the cells using oligo(dT)-cellulose (Ausubel *et al.*, 1992). Ethanol-precipitated mRNA samples were electrophoresed on 1% agarose/formaldehyde gels and transferred to a nylon membrane. Random-primed <sup>32</sup>P-cDNA-probes were synthesized using [ $\alpha$ -<sup>32</sup>P]dCTP and Promega's Prime-a-Gene Labeling System according to manufacturers instructions. Northern blot hybridizations were done according to Sambrook *et al.* (1989), and mRNA signals were detected by autoradiography.

### *Protein isolation, SDS-PAGE, and Western blotting*

A total of  $7\text{--}20 \times 10^6$  cells were trypsinized, washed in PBS, and collected by centrifugation. The cell pellets were suspended in 3 ml of 10% sucrose/PBS containing 1 mM PMSF and homogenized on ice with tissue homogenizer  $2 \times 30$  sec. Homogenized cells were centrifuged at  $10,000 \times g$  for 1 hr at  $+5^\circ\text{C}$  in a Beckman L60 ultracentrifuge using a SW55 rotor (Beckman Instruments, Inc., Palo Alto, CA). The supernatant was analyzed for protein content according to Lowry *et al.* (1951) using bovine serum albumin (BSA) as a standard, and stored at  $-70^\circ\text{C}$ . SDS-PAGE and immunoblotting were done as described (Ylä-Herttuala *et al.*, 1989) with slight modifications. SDS-PAGE was performed using 10% gels in 0.025 M Tris/0.19 M glycine buffer pH 8.3 containing 0.1% SDS (150 V, 75 min). Before the electrophoresis, the samples were heated for 4 min in a boiling water bath. The sample buffer contained 0.063 M Tris-HCl, 2% SDS, 10% glycerol, 10  $\mu\text{M}$  BHT, and 0.001% bromophenol blue pH 6.8. Four micrograms of protein was loaded per lane. Transfer to nitrocellulose membranes for Western blotting was done at  $4^\circ\text{C}$  for 2 hr (200 mA). After the transfer, nonspecific binding sites on the membranes were blocked by incubation with 5% nonfat dried milk proteins at  $4^\circ\text{C}$  for 3 hr. After blotting and blocking, the membranes were incubated overnight with the polyclonal rabbit anti-human recombinant 15-LO antibody (1:500 dilution) (Sigal *et al.*, 1990) in PBS containing 1% nonfat dried milk proteins and 0.05% Tween-20. The membranes were washed  $3 \times 15$  min with the same buffer without antibody, incubated with horseradish peroxidase-conjugated secondary antibody (1:3000 dilution) at  $4^\circ\text{C}$  for 3 hr, and washed  $5 \times 10$  min. 4-Chloro-1-naphthol was used as a color substrate to detect protein bands.

### *Analysis of hydroxy fatty acids*

Cells were trypsinized from confluent 10-cm culture dishes, centrifuged, resuspended in 0.5 ml of PBS, and broken either by mechanical shearing with five strokes in a glass tissue grinder (PA317 cells) or by three freeze-thaw cycles (5 min in dry ice-ethanol, 5 min at  $37^\circ\text{C}$ )

(ECV304 cells). The broken cell suspensions were incubated at  $37^\circ\text{C}$  for 15 min with 50  $\mu\text{M}$  linoleic acid. After incubation, 25  $\mu\text{g}$  of BHT was added to the cell suspensions as an antioxidant and 25  $\mu\text{g}$  of triheptadecanoin as an internal standard. Lipids were extracted, hydrogenated, saponified, esterified, and acetylated, and the hydroxy fatty acids were detected by gas chromatography as described (Nikkari *et al.*, 1995). After lipid extraction, the protein pellet was dissolved in 5% SDS/0.5 N NaOH overnight at  $37^\circ\text{C}$ , and the amount of protein was measured according to Lowry *et al.* (1951) using BSA as a standard.

### *Nuclear extraction and electrophoretic mobility shift assay*

Cells were activated with either TNF- $\alpha$  (100 ng/ml), PMA (100 nM), thapsigargin (1  $\mu\text{M}$ ), or  $\text{H}_2\text{O}_2$  (250  $\mu\text{M}$ ) for 2 hr. Nuclear extracts were prepared (Sen *et al.*, 1996a), and electrophoretic mobility shift assays (EMSAs) were performed (Roy *et al.*, 1998) as previously described. The specificity of the NF- $\kappa\text{B}$  band was demonstrated by treating the nuclear protein extract with an excess of a cold competitor probe or a cold mutant probe (1 bp altered) for 15 min before incubation with a labeled consensus NF- $\kappa\text{B}$  probe (Sen *et al.*, 1996b).

### *Flow cytometric detection of adhesion molecule expression*

Cells were activated with either PMA (100 nM) or TNF- $\alpha$  (100 ng/ml) for 24 hr. For another set of experiments, cells were pretreated for 48 hr with different concentrations of  $\alpha$ -lipoate. The expression of VCAM-1 and ICAM-1 was analyzed by flow cytometry as described (Roy *et al.*, 1998).

### *Adhesion of Jurkat T cells to endothelial cells*

Jurkat T cells were fluorescently labeled with calcein acetoxymethyl ester (calcein-AM) as described (Roy *et al.*, 1998). ECV304 clones were seeded at a density of  $10^4$  cells/well in 96-well tissue culture plates. After 24 hr of seeding, the cells were activated with 100 nM PMA for 24 hr and the cell-cell adhesion assay was performed as described previously (Roy *et al.*, 1998).

## RESULTS

*15-LO mRNA expression*


The isolated 15-LO clones were shown to contain a proviral transcript of ~5.7 kb on Northern blots when hybridized with a random-primed <sup>32</sup>P-labeled 15-LO cDNA probe (Figs. 1A and 2A). None of the control cell lines—a  $\beta$ -galactosidase-producing PA317 clone and untransduced PA317 and ECV304 cells—contained such a transcript, and no endogenous 15-LO expression could be detected. Hybridization with a random-primed cDNA probe for the neomycin phosphotransferase gene resulted in mRNA signals at exactly the same sites, where the 15-LO mRNA signal was detected (Figs. 1B and 2B). This observation confirmed that the whole proviral DNA between the LTRs was transcribed as a full-length transcript, since the 15-LO cDNA insert does not contain a poly(A) signal. In some clones, a smaller mRNA signal of ~2.4 kb was detected when hybridized with the probe for the neomycin phosphotransferase gene (Figs. 1B and 2B). In these clones, the neomycin phosphotransferase gene was transcribed from the internal RSV promoter.

*15-LO protein expression*

Immunoblotting analysis of the PA317 15-LO clones with the polyclonal rabbit anti-human recombinant 15-LO antibody showed the presence of 15-LO protein in the isolated 15-LO clones, whereas 15-LO protein could not be detected in the control cell lines (Fig. 3). No signal was obtained when the primary antibody was omitted (data not shown). The size of the 15-LO protein present in the isolated 15-LO clones was estimated from immunoblots using molecular weight markers. Crude rabbit reticulocyte 15-LO was also included as a control. The size of the crude 15-LO protein and the 15-LO protein in the transduced clones was ~75 kD (Fig. 3), which is in good agreement with previous observations (Sigal *et al.*, 1990; Kühn *et al.*, 1993).

*15-LO enzyme activity*

To detect 15-LO activity, the isolated virus-producing PA317 clones were incubated with



**FIG. 1. Expression of 15-LO mRNA in transduced PA317 cells.** Northern blot analysis of poly(A)<sup>+</sup> RNA samples from PA317 clones. From left: Untransduced control PA317 cells, control lacZ clone LZ3, and 15-LO clones ALO13 to BLO3. Hybridization with random primed cDNA probe for 15-LO (A), neomycin phosphotransferase (B), and glyceraldehyde-3-phosphate dehydrogenase (gAPDH) (C).

linoleic acid and the production of 13-hydroxyoctadecadienoic acid (13-HODE) was measured by gas chromatography. Untransduced PA317 cells and one isolated PA317 clone producing  $\beta$ -galactosidase were used as controls. As shown in Fig. 4, the production of 13-HODE in the untransduced control clone and the  $\beta$ -galactosidase-producing clone was comparable. The 15-LO clones produced about 10–40 times more 13-HODE than the controls, except for one clone, which had a production level comparable to that of the controls. Production of the side products 2- and 9-HODE in the 15-LO clones was only one- to three-fold higher than in the controls. On average, the percent-




FIG. 2. Expression of 15-LO mRNA in transduced ECV304 cells. Northern blot analysis of poly(A)<sup>+</sup> RNA samples from ECV304 clones. From left: Untransduced ECV304 and ECV304 15-LO clones (34–59). Hybridization with random-primed cDNA probe for 15-LO (A), neomycin phosphotransferase (B), and human  $\beta$ -actin (C).





FIG. 3. Expression of 15-LO protein in transduced PA317 cells. Western blot analysis of protein samples from PA317 clones. From left: Control PA317 cells, control lacZ clone LZ3, and 15-LO clones (ALO17 to BLO2). Crude rabbit 15-LO sample was included as an additional control. The Western blot was done using a polyclonal rabbit anti-human recombinant 15-LO antibody (dilution 1:500). Four micrograms protein was loaded per lane.

age of the main product 13-HODE of all the HODEs detected (2-, 9-, and 13-HODE) was 81–89% in the good producers. The gas chromatographic method used in this study (Nikkari *et al.*, 1995) does not give information about the enantiomeric composition of the 15-LO reaction product. However, the enantiomeric specificity has been verified in similarly transduced rabbit aortic smooth muscle cells where the major reaction product after incubation with arachidonic acid was 15-S-hydroxyeicosatetraenoic acid (15-S-HETE), as detected by chiral phase high-performance liquid chromatography (HPLC) (Dr. Hartmut Kühn, personal communication).

On the basis of preliminary enzyme activity studies, clone ALO17 was chosen for the production of amphotropic virus, which was concentrated from the growth medium and was used for the transduction of ECV304 cells. Four ECV304 clones were chosen for enzyme activity analysis: three clones showing high mRNA expression and one clone showing low mRNA



**FIG. 4.** 15-LO enzyme activity in transduced PA317 cells. From left: control PA317 cells, control lacZ clone LZ3, and 15-LO clones (ALO13 to BLO3). Enzyme activity was measured as the amount of 13-HODE produced in ng/mg protein per 15 min after incubation of the cells with 50  $\mu$ M linoleic acid at 37°C. Each point is the mean  $\pm$  SD of duplicate determinations. The amount of 13-HODE produced was measured as described in Materials and Methods.

expression by Northern hybridization. The one clone showing low 15-LO mRNA expression also had low 15-LO enzyme activity, whereas the other clones showing high 15-LO mRNA expression had 10–20 times higher 15-LO enzyme activity than the  $\beta$ -galactosidase-producing control clone ECVLZ5 (Fig. 5). The percentage of 13-HODE of all the HODEs detected in the high producers was 81–100%. Clone ECVLO37 was chosen for further studies.

15-LO mRNA expression levels in the transduced cells correlate with protein expression and enzyme activity. As shown in Fig. 1A, PA317 clone BLO2 had a very weak hybridization signal for 15-LO probe, clone ALO17 had somewhat stronger signal, and the signal in clone BLO1 was the strongest. Likewise, clone BLO2 showed the weakest signal for 15-LO protein production and enzyme activity, whereas clone BLO1 had the highest production levels among these three clones (Figs. 3 and 4). No endogenous 15-LO mRNA or protein expression could be detected in the transduced cells.

#### NF- $\kappa$ B activation


When nuclear protein extracts of the human ECV304 clone overexpressing 15-LO (ECVLO)

were examined by EMSA using a labeled NF- $\kappa$ B-binding oligonucleotide, a distinct NF- $\kappa$ B retardation band was observed (Fig. 6). In these cells, stimulation with TNF- $\alpha$  (100 ng/ml), PMA (100 nM), thapsigargin (1  $\mu$ M), or H<sub>2</sub>O<sub>2</sub> (250  $\mu$ M) markedly potentiated NF- $\kappa$ B activation as compared to a  $\beta$ -galactosidase-expressing clone (ECVLZ). Competition assays with cold consensus and mutant NF- $\kappa$ B oligonucleotides confirmed the specificity of the NF- $\kappa$ B band.

#### Flow cytometric detection of adhesion molecule expression

Flow cytometric analysis showed that the level of constitutive ICAM-1 expression was similar in ECVLO cells and in the corresponding  $\beta$ -galactosidase-expressing ECVLZ control cells. However, the inducibility of NF- $\kappa$ B-regulated ICAM-1 expression in response to PMA (100 nM, 24 hr) or TNF- $\alpha$  (100 ng/ml, 24 hr) stimulation was markedly higher in ECVLO cells (Fig. 7). This is consistent with our previous observation that activation of NF- $\kappa$ B in response to different stimuli is potentiated in the presence of 15-LO overexpression. We further studied whether this inducible ICAM-1 expression in ECVLO cells was antioxidant-sen-





**FIG. 5.** 15-LO enzyme activity in transduced ECV304 cells. **A.** From left: Control ECV304 cells, control lacZ clone ECVLZ5, and 15-LO clones ECVLO13, ECVLO37, ECVLO42, and ECVLO53. Enzyme activity was measured as the amount of 13-HODE produced in ng/mg protein per 15 min after incubation of the cells with 50  $\mu$ M linoleic acid at 37°C. Each point is the mean  $\pm$  SD of duplicate determinations. The amount of 13-HODE produced was measured as described in Materials and Methods. **B.** Gas chromatographic analysis after incubation of endothelial cells with linoleic acid. Hydroperoxy fatty acids were hydrogenated, methylated, and acetylated before gas chromatography. 20:0, docosanoic acid; 2-OH-18:0, 2-hydroxy octadecanoic acid; 9-OH-18:0, 9-hydroxy octadecanoic acid; 13-OH-18:0, 13-hydroxy octadecanoic acid. Samples are the same as in A.






FIG. 6. Potentiation of NF-κB activation by overexpression of 15-LO in human endothelial cells in response to TNF-α, PMA, thapsigargin, and hydrogen peroxide. Cells were stimulated for 2 hr before nuclear extraction and EMSA. Competition assays with consensus and mutant NF-κB oligonucleotides confirm the specificity of the NF-κB band. Bars represent densitometric results obtained from scanning the respective autoradiograms. ECVLO, transduced ECV304 cells expressing human 15-lipoxygenase; ECVLZ, transduced ECV304 cells expressing *E. coli* β-galactosidase.





FIG. 7. Induction of ICAM-1 expression in ECVLO and ECVLZ cells in response to PMA and TNF-α stimulation. Cells were stimulated for 24 hr. Results were obtained by flow cytometric detection using FITC-labeled monoclonal antibody against ICAM-1. ICAM-1 expression is presented as percent increase compared to nonactivated cells. Histogram represents one of three essentially identical experiments.

sitive by pretreating the cells with different concentrations of an antioxidant α-lipoate. The results in Fig. 8 show that α-lipoate pretreatment had no effect on the constitutive ICAM-1 expression in ECVLO cells, but inhibited the PMA or TNF-α induced ICAM-1 expression in a dose-dependent manner. These results further support the hypothesis that oxidative stress in the ECVLO cells is involved in the NF-κB-induced ICAM-1 expression.


Under resting conditions, both ECVLO and ECVLZ control cells were almost devoid of VCAM-1 expression, but consistent with the ICAM-1 results, inducibility of VCAM-1 in response to PMA or TNF-α stimulation was much stronger in ECVLO cells as compared to the β-galactosidase-expressing control cells (Fig. 9).




**FIG. 8. Dose-dependent inhibition of PMA and TNF- $\alpha$  stimulated ICAM-1 induction in ECVLO cells by  $\alpha$ -lipoate.** Cells were pretreated with  $\alpha$ -lipoate for 48 hr and then treated for 24 hr with the indicated compounds. Results were obtained by flow cytometric detection using FITC-labeled monoclonal antibody against ICAM-1.

#### Adhesion of Jurkat T cells to endothelial cells

The adherence of Jurkat T cells on ECVLO cells was markedly induced in response to PMA stimulation, whereas the adherence on ECVLZ cells was not affected (Fig. 10).



**FIG. 9. Induction of VCAM-1 expression in ECVLO and ECVLZ cells in response to PMA and TNF- $\alpha$  stimulation.** Cells were stimulated for 24 hr. Results were obtained by flow cytometric detection using a monoclonal antibody against VCAM-1 and a FITC-labeled secondary antibody. VCAM-1 expression is presented as percent increase compared to nonactivated cells. Data are mean  $\pm$  SD of at least three experiments.



**FIG. 10. Increased adherence of Jurkat T cells to ECVLO cells in response to PMA stimulation.** Cells were stimulated with 100 nM PMA for 24 hr and then co-cultured with calcein-AM-labeled Jurkat T cells for 1 hr. The results are expressed as percent increase in the number of adhered Jurkat T cells to ECVLO and ECVLZ cells following PMA stimulation. Three separate experiments were done in triplicate.

## DISCUSSION

In spite of the fact that 15-LO expression and enzyme activity in early atherosclerotic lesions have been clearly established (Kühn *et al.*, 1994, 1997) and that over 100-fold induction of 15-LO expression is seen in early fatty streak lesions (Hiltunen *et al.*, 1995), exact mechanisms for the proatherogenic role of 15-LO have remained unclear. Our working hypothesis was that, in addition to its possible role in LDL oxidation, 15-LO might have some other atherogenic effects in endothelial cells. This concept is also supported by a significant antiatherosclerotic effect of a 15-LO inhibitor in hypercholesterolemic rabbits, which is difficult to explain only on the basis of the inhibition of LDL oxidation (Sendobry *et al.*, 1997; Bocan *et al.*, 1998). In this study, we show that retrovirus-mediated stable gene transfer of human 15-LO leads to high expression of 15-LO mRNA, protein, and enzyme activity, potentiates VCAM-1 and ICAM-1 expression via NF- $\kappa$ B-mediated mechanism, and induces adhesion of T cells on the transduced endothelial cells.

Recent evidence suggests that reactive oxygen species and lipid hydroperoxides act as signaling molecules for the regulation of genes involved in atherogenesis. 9- and 13-HODEs have been shown to activate transcription factor peroxisome proliferator activated receptor  $\gamma$  (PPAR $\gamma$ ) (Nagy *et al.*, 1998) and susceptibility of mice to atherosclerosis is genetically associated with the accumulation of lipid peroxidation products, induction of inflammatory genes, and the activation of NF- $\kappa$ B (Liao *et al.*, 1993, 1994). It has been clearly established that reactive oxygen species activate several transcription factors, including NF- $\kappa$ B (Schreck *et al.*, 1992; Andalibi *et al.*, 1993; Sen and Packer, 1996), which is present in atherosclerotic lesions in its activated form (Brand *et al.*, 1996). NF- $\kappa$ B regulates the expression of several genes expressed in atherosclerotic lesions, such as VCAM-1 (Cybulsky and Gimbrone, 1991; Li *et al.*, 1993a,b; O'Brien *et al.*, 1993) and ICAM-1 (Poston *et al.*, 1992; Printseva *et al.*, 1992). TNF- $\alpha$  activates NF- $\kappa$ B (Baeuerle and Henkel, 1994), and induces NF- $\kappa$ B-mediated expression of VCAM-1 (Rice and Bevilacqua, 1989) and ICAM-1 (Pober *et al.*, 1986; Roebuck *et al.*, 1995). It has also been shown that addition of the 15-LO product 13-hydroperoxyoctadecadienoic acid (13-HPODE) to endothelial cells in the presence of TNF- $\alpha$  increased the expression of VCAM-1 (Khan *et al.*, 1995). Also, 15-LO metabolites 15(S)-hydroperoxyeicosatetraenoic acid (15(S)-HPETE) and 12(S)-HETE induced endothelial adhesion molecule expression, and adhesion and transendothelial migration of monocyte-like HL-60 cells (Sultana *et al.*, 1996). However, these metabolites can be provided by cyclooxygenases as well as by 15-LO (Camacho *et al.*, 1995).

15-LO expression in the transduced ECV304 cells leads to increased oxidative stress as indicated by lowered  $\alpha$ -tocopherol and ubiquinol levels in these cells as compared to the control ECVLZ cells (data not shown). This and blocking of the induction of ICAM-1 in the 15-LO-transduced cells by an antioxidant  $\alpha$ -lipoate suggests that 15-LO is linked to the redox-sensitive signal transduction cascade. The constitutive expression of the adhesion molecules ICAM-1 and VCAM-1 were similar in the ECVLO and ECVLZ cells, but the expression of

these adhesion molecules was induced in the ECVLO cells when stimulated with PMA or TNF- $\alpha$ . 15-LO inhibitor (eicosatetraenoic acid, ETYA) attenuated these findings (data not shown), although data obtained with relatively unspecific inhibitors should be interpreted with caution. Wölle *et al.* (1996) achieved similar results for VCAM-1 expression after transient transfection of 15-LO into bovine endothelial cells.

The adherence of Jurkat T cells on ECVLO cells was greatly induced after PMA stimulation, whereas the adherence on ECVLZ cells was not affected. VCAM-1 is a specific receptor for lymphocytes and monocytes, because its ligand, the very late activation antigen-4 (VLA-4) is expressed only on lymphocytes and monocytes, but not on neutrophils (Rice *et al.*, 1990). ICAM-1, on the other hand, is a ligand for lymphocyte function-associated antigen 1 (LFA-1) and Mac-1, which are expressed in all leukocytes (Makgoba *et al.*, 1988; Albelda, 1991). Substantial amounts of T lymphocytes are present in human atherosclerotic lesions, where they can have important effects on the inflammatory aspects of atherosclerosis. It is concluded that 15-LO may be involved in the early events of atherogenesis not only by inducing the oxidative modification of LDL, but also as a mediator of the adhesion of T cells on the endothelium via production of reactive oxygen species that can activate NF- $\kappa$ B and potentiate expression of VCAM-1 and ICAM-1 in response to various inflammatory stimuli. Inhibition of 15-LO activity could be one potential way to reduce atherogenesis in human arteries.

## ACKNOWLEDGMENTS

This work was supported by grants from Finnish Cultural Foundation, Finnish Foundation for Cardiovascular Research, The Academy of Finland, Ida Montin Foundation, Sigrid Jusélius Foundation, and Aarne and Aili Turunen Foundation. Authors thank Ms. Mervi Nieminen for skillful technical assistance and Ms. Marja Poikolainen for preparing the manuscript.

## REFERENCES

- ALBELDA, S.M. (1991). Endothelial and epithelial cell adhesion molecules. *Am. J. Respir. Cell. Mol. Biol.* **4**, 195–203.
- ANDALIBI, A., LIAO, F., IMES, S., FOGELMAN, A.M., and LUSIS, A.J. (1993). Oxidized lipoproteins influence gene expression by causing oxidative stress and activating the transcription factor NF-kappa B. *Biochem. Soc. Trans.* **21**, 651–655.
- AUSUBEL, F.M., BRENT, R., KINGSTON, R.E., MOORE, D.D., SEIDMAN, J.G., SMITH, J.A., and STRUHL, K. (1992). *Current Protocols in Molecular Biology*. (Greene Publishing Associates and Wiley-Interscience, John Wiley & Sons, New York).
- BAEUERLE, P.A., and HENKEL, T. (1994). Function and activation of NF- $\kappa$ B in the immune system. *Annu. Rev. Immunol.* **12**, 141–179.
- BECK, E., LUDWIG, G., AUERSWALD, E.A., REISS, B., and SCHALLER, H. (1982). Nucleotide sequence and exact localization of the neomycin phosphotransferase gene from transposon Tn5. *Gene* **19**, 327–336.
- BENZ, D.J., MOL, M., EZAKI, M., MORI-ITO, N., ZELÁN, I., MIYANOHARA, A., FRIEDMANN, T., PARTHASARATHY, S., STEINBERG, D., and WITZTUM, J.L. (1995). Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblasts expressing high levels of human 15-lipoxygenase. *J. Biol. Chem.* **270**, 5191–5197.
- BOCAN, T.M.A., ROSEBURY, W.S., BAK MUELLER, S., KUCHERA, S., WELCH, K., DAUGHERTY, A., and CORNICELLI, J.A. (1998). A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. *Atherosclerosis* **136**, 203–216.
- BRAND, K., PAGE, S., ROGLER, G., BARTSCH, A., BRANDL, R., KNUECHEL, R., PAGE, M., KALTSCHMIDT, C., BAEUERLE, P.A., and NEUMEIER, D. (1996). Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. *J. Clin. Invest.* **97**, 1715–1722.
- CAMACHO, M., GODESSART, N., ANTÓN, R., GARCÍA, M., and VILA, L. (1995). Interleukin-1 enhances the ability of cultured human umbilical vein endothelial cells to oxidize linoleic acid. *J. Biol. Chem.* **270**, 17279–17286.
- CYBULSKY, M.I., and GIMBRONE, M.A. Jr. (1991). Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. *Science* **251**, 788–791.
- DERIAN, C.K., and LEWIS, D.F. (1992). Activation of 15-lipoxygenase by low density lipoprotein in vascular endothelial cells. Relationship to the oxidative modification of low density lipoprotein. *Prostagland. Leukotrien. Essent. Fatty Acids.* **45**, 49–57.
- GILBOA, E., EGLITIS, M.A., KANTOFF, P.W., and ANDERSON, W.F. (1986). Transfer and expression of cloned genes using retroviral vectors. *BioTechniques* **4**, 504–512.
- HARATS, D., KURIHARA, H., LEVKOVITZ, H., SHAISH, A., and SIGAL, E. (1997). 15-lipoxygenase overexpression induces atherosclerosis in LDL deficient mice. *Atherosclerosis* **134**, 279.
- HILTUNEN, T., LUOMA, J., NIKKARI, T., and YLÄHERTTUALA, S. (1995). Induction of 15-lipoxygenase mRNA and protein in early atherosclerotic lesions. *Circulation* **92**, 3297–3303.
- KALNINS, A., OTTO, K., RÜTHER, U., and MÜLLER-HILL, B. (1983). Sequence of the lacZ gene of *Escherichia coli*. *EMBO J.* **2**, 593–597.
- KHAN, B.V., PARTHASARATHY, S.S., ALEXANDER, R.W., and MEDFORD, R.M. (1995). Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. *J. Clin. Invest.* **95**, 1262–1270.
- KÜHN, H., BARNETT, J., GRUNBERGER, D., BAECKER, P., CHOW, J., NGUYEN, B., BURSZTYN-PETTEGREW, H., CHAN, H., and SIGAL, E. (1993). Overexpression, purification and characterization of human recombinant 15-lipoxygenase. *Biochim. Biophys. Acta* **1169**, 80–89.
- KÜHN, H., BELKNER, J., ZAISS, S., FÄHRENKLEMPER, T., and WOHLFEIL, S. (1994). Involvement of 15-lipoxygenase in early stages of atherogenesis. *J. Exp. Med.* **179**, 1903–1911.
- KÜHN, H., HEYDECK, D., HUGOU, I., and GNIWOTTA, C. (1997). In vivo action of 15-lipoxygenase in early stages of human atherogenesis. *J. Clin. Invest.* **99**, 888–893.
- LI, H., CYBULSKY, M.I., GIMBRONE, M.A. Jr., and LIBBY, P. (1993a). An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. *Arterioscler. Thromb.* **13**, 197–204.
- LI, H., CYBULSKY, M.I., GIMBRONE, M.A. Jr., and LIBBY, P. (1993b). Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. *Am. J. Pathol.* **143**, 1551–1559.
- LIAO, F., ANDALIBI, A., DEBEER, F.C., FOGELMAN, A.M., and LUSIS, A.J. (1993). Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. *J. Clin. Invest.* **91**, 2572–2579.
- LIAO, F., ANDALIBI, A., QIAO, J.-H., ALLAYEE, H., FOGELMAN, A.M., and LUSIS, A.J. (1994). Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. *J. Clin. Invest.* **94**, 877–884.
- LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L., and RANDALL, R.J. (1951). Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193**, 265–275.
- MAKGOBA, M.W., SANDERS, M.E., LUCE, G.E.G., DUSTIN, M.L., SPRINGER, T.A., CLARK, E.A., MANNONI, P., and SHAW, S. (1988). ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. *Nature* **331**, 86–88.
- MANN, R., MULLIGAN, R.C., and BALTIMORE, D.

- (1983). Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. *Cell* **33**, 153–159.
- McNALLY, A.K., CHISOLM III, G.M., MOREL, D.W., and CATHCART, M.K. (1990). Activated human monocytes oxidize low-density lipoprotein by a lipoxygenase-dependent pathway. *J. Immunol.* **145**, 254–259.
- MILLER, A.D., and BUTTIMORE, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. *Mol. Cell. Biol.* **6**, 2895–2902.
- MIYANOHARA, A., SHARKEY, M.F., WITZTUM, J.L., STEINBERG, D., and FRIEDMANN, T. (1988). Efficient expression of retroviral vector-transduced human low density lipoprotein (LDL) receptor in LDL receptor-deficient rabbit fibroblasts in vitro. *Proc. Natl. Acad. Sci. USA* **85**, 6538–6542.
- NAGY, L., TONONNOZ, P., ALVAREZ, J.G.A., CHEN, H., and EVANS, R.M. (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR $\gamma$ . *Cell* **93**, 229–240.
- NIKKARI, T., MALO-RANTA, U., HILTUNEN, T., JAAKKOLA, O., and YLÄ-HERTTUALA, S. (1995). Monitoring of lipoprotein oxidation by gas chromatographic analysis of hydroxy fatty acids. *J. Lipid. Res.* **36**, 200–207.
- O'BRIEN, K.D., ALLEN, M.D., McDONALD, T.O., CHAIT, A., HARLAN, J.M., FISHBEIN, D., McCARTY, J., FERGUSON, M., HUDKINS, K., BENJAMIN, C.D., LOBB, R., and ALPERS, C.E. (1993). Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. *J. Clin. Invest.* **92**, 945–951.
- PARTHASARATHY, S., WIELAND, E., and STEINBERG, D. (1989). A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. *Proc. Natl. Acad. Sci. USA* **86**, 1046–1050.
- POBER, J.S., GIMBRONE, M.A. Jr., LAPIERRE, L.A., MENDRICK, D.L., FIERIS, W., ROTHLEIN, R., and SPRINGER, T.A. (1986). Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. *J. Immunol.* **137**, 1893–1896.
- POSTON, R.N., HASKARD, D.O., COUCHER, J.R., GALL, N.P., and JOHNSON-TIDEY, R.R. (1992). Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. *Am. J. Pathol.* **140**, 665–673.
- PRINTSEVA, O.Y., PECLO, M.M., and GOWN, A.M. (1992). Various cell types in human atherosclerotic lesions express ICAM-1. Further immunocytochemical and immunochromatological studies employing monoclonal antibody 10F3. *Am. J. Pathol.* **140**, 889–896.
- RANKIN, S.M., PARTHASARATHY, S., and STEINBERG, D. (1991). Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. *J. Lipid Res.* **32**, 449–456.
- RICE, C.E., and BEVILACQUA, M.P. (1989). An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. *Science* **246**, 1303–1306.
- RICE, G.E., MUNRO, J.M., and BEVILACQUA, M.P. (1990). Inducible cell adhesion molecule 110 (INCAM-110) is an endothelial receptor for lymphocytes. A CD11/CD18-independent adhesion mechanism. *J. Exp. Med.* **171**, 1369–1374.
- ROEBUCK, K.A., RAHMAN, A., LAKSHMINARAYANAN, V., JANAKIDEVI, K., and MALIK, A.B. (1995). H202 and tumor necrosis factor-alpha activate intercellular adhesion molecule 1 (ICAM-1) gene transcription through distinct cis-regulatory elements within the ICAM-1 promoter. *J. Biol. Chem.* **270**, 18966–18974.
- ROSS, R. (1993). The pathogenesis of atherosclerosis: A perspective for the 1990s. *Nature* **372**, 801–809.
- ROY, S., SEN, C.K., KOBUCHI, H., and PACKER, L. (1998). Antioxidant regulation of phorbol ester-induced adhesion of human jurkat T-cells to endothelial cells. *Free Radic. Biol. Med.* **25**, 229–241.
- SAMBROOK, J., FRITSCH, E.F., and MANIATIS, T. (1989). *Molecular Cloning: A Laboratory Manual*, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
- SCHRECK, R., ALBERMANN, K., and BAEUERLE, P.A. (1992). Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells. *Free Rad. Res. Comms.* **17**, 221–237.
- SEN, C.K., and PACKER, L. (1996). Antioxidant and redox regulation of gene transcription. *FASEB J.* **10**, 709–720.
- SEN, C.K., TRABER, K.E., and PACKER, L. (1996a). Inhibition of NF-kappa B activation in human T-cell lines by anetholdithiolthione. *Biochim. Biophys. Res. Commun.* **218**, 148–153.
- SEN, C.K., ROY, S., and PACKER, L. (1996b). Involvement of intracellular Ca<sup>2+</sup> in oxidant-induced NF-kappa B activation. *FEBS Lett.* **385**, 58–62.
- SENDOBRY, S.M., CORNICELLI, J.A., WELCH, K., BOCAN, T., TAIT, B., TRIVEDI, B.K., COLBRY, N., DYER, R.D., FEINMARK, S.J., and DAUGHERTY, A. (1997). Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. *Br. J. Pharm.* **120**, 1199–1206.
- SHARKEY, M.F., MIYANOHARA, A., ELAM, R.L., FRIEDMANN, T., and WITZTUM, J.L. (1990). Post-transcriptional regulation of retroviral vector-transduced low density lipoprotein receptor activity. *J. Lipid Res.* **31**, 2167–2178.
- SHEN, J., HERDERICK, E., CORNHILL, J.F., ZSIGMOND, E., KIM, H-S., KÜHN, H., GUEVARA, N.V., and CHAN, L. (1996). Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. *J. Clin. Invest.* **98**, 2201–2208.
- SIGAL, E. (1991). The molecular biology of mammalian arachidonic acid metabolism. *Am. J. Physiol.* **260**, L13–L28.
- SIGAL, E., CRAIK, C.S., HIGHLAND, E., GRUNBERGER, D., COSTELLO, L.L., DIXON, R.A.F., and NADEL, J.A. (1988). Molecular cloning and primary structure of human 15-lipoxygenase. *Biochem. Biophys. Res. Commun.* **157**, 457–464.

- SIGAL, E., GRUNBERGER, D., HIGHLAND, E., GROSS, C., DIXON, R.A.F., and CRAIK, C.S. (1990). Expression of cloned human reticulocyte 15-lipoxygenase and immunological evidence that 15-lipoxygenases of different cell types are related. *J. Biol. Chem.* **265**, 5113–5120.
- SPARROW, C.P., and OLSZEWSKI, J. (1992). Cellular oxidative modification of low density lipoprotein does not require lipoxygenases. *Proc. Natl. Acad. Sci. USA* **89**, 128–131.
- SPARROW, C.P., PARTHASARATHY, S., and STEINBERG, D. (1988). Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. *J. Lipid Res.* **29**, 745–753.
- SULTANA, C., SHEN, Y., RATTAN, V., and KALRA, V.K. (1996). Lipoxygenase metabolites induced expression of adhesion molecules and transendothelial migration of monocyte-like HL-60 cells is linked to protein kinase C activation. *J. Cell. Physiol.* **167**, 477–487.
- SUN, D., and FUNK, C.D. (1996). Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. *J. Biol. Chem.* **271**, 24055–24062.
- VAN BEVEREN, C., GODDARD, J.G., BERNS, A., and VERMA, I.M. (1980). Structure of Moloney murine leukemia viral DNA: Nucleotide sequence of the 5' long terminal repeat and adjacent cellular sequences. *Proc. Natl. Acad. Sci. USA* **77**, 3307–3311.
- WÖLLE, J., WELCH, K.A., DEVAL, L.J., CORNICELLI, J.A., and SAXENA, U. (1996). Transient overexpression of human 15-lipoxygenase in aortic endothelial cells enhances tumor necrosis factor-induced vascular cell adhesion molecule-1 gene expression. *Biochim. Biophys. Res. Commun.* **220**, 310–314.
- YLÄ-HERTTUALA, S. (1998). Is oxidized low-density lipoprotein present *in vivo*? *Curr. Opin. Lipidol.* **9**, 337–344.
- YLÄ-HERTTUALA, S., PALINSKI, W., ROSENFELD, M.E., PARTHASARATHY, S., CAREW, T.E., BUTLER, S., WITZTUM, J.L., and STEINBERG, D. (1989). Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. *J. Clin. Invest.* **84**, 1086–1095.
- YLÄ-HERTTUALA, S., ROSENFELD, M.E., PARTHASARATHY, S., GLASS, C.K., SIGAL, E., WITZTUM, J.L., and STEINBERG, D. (1990). Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. *Proc. Natl. Acad. Sci. USA* **87**, 6959–6963.
- YLÄ-HERTTUALA, S., ROSENFELD, M.E., PARTHASARATHY, S., SIGAL, E., SÄRKIOJA, T., WITZTUM, J.L., and STEINBERG, D. (1991). Gene expression in macrophage-rich human atherosclerotic lesions. *J. Clin. Invest.* **87**, 1146–1152.
- YLÄ-HERTTUALA, S., LUOMA, J., VIITA, H., HILTUNEN, T., SISTO, T., and NIKKARI, T. (1995). Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. *J. Clin. Invest.* **95**, 2692–2698.

Address reprint requests to:  
 Seppo Ylä-Herttuala, M.D., Ph.D.  
 A.I. Virtanen Institute  
 University of Kuopio  
 P.O. Box 1627  
 FIN-70211 Kuopio  
 Finland  
 E-mail: seppo.ylaherttuala@uku.fi

**This article has been cited by:**

1. Robin N. Poston. 2019. Atherosclerosis: integration of its pathogenesis as a self-perpetuating propagating inflammation: a review. *Cardiovascular Endocrinology & Metabolism* **8**:2, 51-61. [[Crossref](#)]
2. Daniel W. Carr, Sonemany Salinthone. Lipoic Acid, Inflammation and Diseases of the Nervous System 2349-2368. [[Crossref](#)]
3. Jing Li, Jingjing Rao, Yun Liu, Yonggang Cao, Yueming Zhang, Qianlong Zhang, Daling Zhu. 2013. 15-Lipoxygenase Promotes Chronic Hypoxia-Induced Pulmonary Artery Inflammation via Positive Interaction With Nuclear Factor- $\kappa$ B. *Arteriosclerosis, Thrombosis, and Vascular Biology* **33**:5, 971-979. [[Crossref](#)]
4. Gisela Adrienne Weiss, Heinz Troxler, Glynis Klinke, Daniela Rogler, Christian Braegger, Martin Hersberger. 2013. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. *Lipids in Health and Disease* **12**:1, 89. [[Crossref](#)]
5. G.A. Contreras, W. Raphael, S.A. Mattmiller, J. Gandy, L.M. Sordillo. 2012. Nonesterified fatty acids modify inflammatory response and eicosanoid biosynthesis in bovine endothelial cells. *Journal of Dairy Science* **95**:9, 5011-5023. [[Crossref](#)]
6. Anca D. Dobrian, David C. Lieb, Banumathi K. Cole, David A. Taylor-Fishwick, Swarup K. Chakrabarti, Jerry L. Nadler. 2011. Functional and pathological roles of the 12- and 15-lipoxygenases. *Progress in Lipid Research* **50**:1, 115-131. [[Crossref](#)]
7. Kristina Norén Danielsson, Ellen Knutsen Rydberg, Madeleine Ingelsten, Levent M. Akyürek, Pernilla Jirholt, Christina Ullström, Gun-Britt Forsberg, Jan Borén, Olov Wiklund, Lillemor Mattsson Hultén. 2008. 15-Lipoxygenase-2 expression in human macrophages induces chemokine secretion and T cell migration. *Atherosclerosis* **199**:1, 34-40. [[Crossref](#)]
8. Helena Viita, Johanna Markkanen, Emmi Eriksson, Markku Nurminen, Kati Kinnunen, Mohan Babu, Tommi Heikura, Sanna Turpeinen, Svetlana Laidinen, Teemu Takalo, Seppo Ylä-Herttuala. 2008. 15-Lipoxygenase-1 Prevents Vascular Endothelial Growth Factor A- and Placental Growth Factor-Induced Angiogenic Effects in Rabbit Skeletal Muscles via Reduction in Growth Factor mRNA Levels, NO Bioactivity, and Downregulation of VEGF Receptor 2 Expression. *Circulation Research* **102**:2, 177-184. [[Crossref](#)]
9. Hartmut Kuhn, Pavlos Chaitidis, Jana Roffeis, Matthias Walther. 2007. Arachidonic Acid Metabolites in the Cardiovascular System: The Role of Lipoxygenase Isoforms in Atherogenesis With Particular Emphasis on Vascular Remodeling. *Journal of Cardiovascular Pharmacology* **50**:6, 609-620. [[Crossref](#)]
10. Jonas Wittwer, Martin Hersberger. 2007. The two faces of the 15-lipoxygenase in atherosclerosis. *Prostaglandins, Leukotrienes and Essential Fatty Acids* **77**:2, 67-77. [[Crossref](#)]
11. Nitin T. Aggarwal, Blythe B. Holmes, Lijie Cui, Helena Viita, Seppo Ylä-Herttuala, William B. Campbell. 2007. Adenoviral expression of 15-lipoxygenase-1 in rabbit aortic endothelium: role in arachidonic acid-induced relaxation. *American Journal of Physiology-Heart and Circulatory Physiology* **292**:2, H1033-H1041. [[Crossref](#)]
12. Olivier Barbier, Lyne Villeneuve, Virginie Bocher, Coralie Fontaine, Ines Pineda Torra, Christian Duhem, Vladimir Kosykh, Jean-Charles Fruchart, Chantal Guillemette, Bart Staels. 2003. The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor  $\alpha$  and  $\gamma$  Target Gene. *Journal of Biological Chemistry* **278**:16, 13975-13983. [[Crossref](#)]
13. Hartmut Kuhn, Matthias Walther, Ralf Jürgen Kuban. 2002. Mammalian arachidonate 15-lipoxygenases. *Prostaglandins & Other Lipid Mediators* **68-69**, 263-290. [[Crossref](#)]
14. Michael E. Rosenfeld. 2002. Leukocyte Recruitment Into Developing Atherosclerotic Lesions. *Arteriosclerosis, Thrombosis, and Vascular Biology* **22**:3, 361-363. [[Crossref](#)]
15. Dagmar Heydeck, Joanne M. Upston, Helena Viita, Seppo Ylä-Herttuala, Roland Stocker. 2001. Oxidation of LDL by rabbit and human 15-lipoxygenase: prevalence of nonenzymatic reactions. *Journal of Lipid Research* **42**:7, 1082-1088. [[Crossref](#)]
16. CHANDAN K. SEN, SASHWATI ROY. 2001. Antioxidant regulation of cell adhesion. *Medicine and Science in Sports and Exercise* **33**:3, 377-381. [[Crossref](#)]
17. Regina Brigelius-Flohé, Stefanie Maurer, Katharina Lötzer, Gaby-Fleur Böl, Hanna Kallionpää, Paulina Lehtolainen, Helena Viita, Seppo Ylä-Herttuala. 2000. Overexpression of PHGPx inhibits hydroperoxide-induced oxidation,



NF $\kappa$ B activation and apoptosis and affects oxLDL-mediated proliferation of rabbit aortic smooth muscle cells. *Atherosclerosis* **152**:2, 307-316. [[Crossref](#)]

18. Roberto Tolando, Aleksandra Jovanović, Regina Brigelius-Flohé, Fulvio Ursini, Matilde Maiorino. 2000. Reactive oxygen species and proinflammatory cytokine signaling in endothelial cells: effect of selenium supplementation. *Free Radical Biology and Medicine* **28**:6, 979-986. [[Crossref](#)]
19. Helena Viita, Seppo Ylä-Herttuala. Effects of Lipoxygenases on Gene Expression in Mammalian Cells 339-358. [[Crossref](#)]